About this site
Retatrutide Peptide is an independent editorial project. It publishes sourced explainers about one compound, retatrutide, for readers who want the trial numbers without the marketing.
What this site is
A small library of long-form articles about retatrutide (LY3437943), the triple GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly. The site covers what the molecule is, how it works, what the phase 2 and phase 3 trials found, its side effects, its regulatory status, and the market that has grown around it before approval. It does not sell anything, run advertising, collect analytics or set cookies.
Method
- Every number has a source on the same page. Trial results come from peer-reviewed publications identified by DOI, from ClinicalTrials.gov registry records identified by NCT number, or, for phase 3 topline results not yet published, from the company's press releases cited by URL.
- Sources are machine-checked. Before publication, every DOI on the site is resolved against the CrossRef API and every NCT number against the ClinicalTrials.gov API v2. A source that fails to resolve is removed.
- Evidence levels are labelled. Peer-reviewed results and company announcements are both reported, and the text says which is which.
- No testimonials, no anecdotes, no invented reviews. Where the site discusses what people say online, it does so without quoting or naming anyone.
- Doses are trial doses. Any dose mentioned is the protocol of a cited trial, never a suggestion.
Why there is a link to a supplier
Some readers are laboratory buyers looking for research-grade retatrutide with a verifiable certificate of analysis. Each article carries one plain link to the RP listing at OXpeptides (https://oxpeptides.com/products/rp), labelled research use only. The site has no affiliate arrangement and receives no payment for clicks or orders. The link is there because the question comes up, and a named listing with a published certificate is a more honest answer than silence.
Corrections
If a figure on this site does not match its cited source, or a source has been superseded, write to editor@retatrutide-peptide.com with the page URL and the correction. Corrections are applied to the page and the updated date is changed. Substantive corrections are noted at the bottom of the article concerned.
What this site is not
It is not medical advice, not a pharmacy, not a supplier, and not affiliated with Eli Lilly and Company, the FDA or any regulator. Retatrutide is an investigational compound, not approved by the FDA or the EMA. See the editorial policy for the rules every article follows, or start with the main guide, reta peptide: what it is, how it works, what the trials show.